Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD5069 + durvalumab + tremelimumab
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (AZD5069), Intravenous (durvalumab), Intravenous (tremelimumab)
01
Overview
AZD5069 + durvalumab + tremelimumab is a combination therapy involving three investigational and/or approved drugs: AZD5069, a small molecule selective antagonist of the CXC chemokine receptor 2 (CXCR2); durvalumab, a monoclonal antibody and immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1); and tremelimumab, a monoclonal antibody checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). The combination is being investigated for synergistic anti-tumor effects by inhibiting pro-tumor immune signaling (via CXCR2), blocking immunosuppressive signals (PD-L1), and promoting T-cell-mediated anti-tumor immunity (CTLA-4). It is in clinical studies for advanced solid tumors, hepatocellular carcinoma (HCC), and recurrent/metastatic squamous cell carcinoma of the head and neck. The combination is currently in early-phase clinical trials.
- Brand names
- Imfinzi (durvalumab)tremelimumab (no widely used brand name)AZD5069 (no approved brand or trade name)
- Other names
- AZD5069 + durvalumab + tremelimumab
02
Targets
CXCR2 (C-X-C Motif Chemokine Receptor 2)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on AZD5069 + durvalumab + tremelimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD5069 + durvalumab + tremelimumab.